Revenue Dynamics YoY (Last Twelve Months): Tekmira Pharmaceuticals (ABUS)

Public company logo of arbutusbio.com (ABUS)

Does the lipid particle patent portfolio ensure a stable cash flow? The rolling 12-month sales growth rate year-over-year provides the answer, where the 1140.50 indicator determines the metric's value. Arbutus Biopharma (ABUS) revenues are based on licensing royalties from pharma behemoths for drug delivery. Additionally, the company is implementing automated RNA synthesis stations to accelerate the development of antiviral drugs.

ABUS (Arbutus Biopharma Corporation) Revenue Growth YoY (Last 12 Months) history from 02/11/2024 to 11/18/2026

arbutusbio.com - analytical breakdowns and key metrics (ABUS)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Analysis of all company metrics:ABUS Arbutus Biopharma
Product sample of Arbutus Biopharma

This indicator measures relative revenue dynamics over a rolling twelve-month period, allowing for a real-time assessment of business scaling rates by comparing current income with the same window from the previous year on a daily basis. By analyzing the annual growth of operating sales revenue (TTM), an investor can gauge the monetization efficiency of Arbutus Biopharma (ABUS), where the stability of patent licensing royalties minimizes the impact of production costs on the bottom line.